GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Enterprise Value

RemeGen Co (SHSE:688331) Enterprise Value : ¥16,655 Mil (As of Dec. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RemeGen Co's Enterprise Value is ¥16,655 Mil. RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-1,539 Mil. Therefore, RemeGen Co's EV-to-EBIT ratio for today is -10.82.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, RemeGen Co's Enterprise Value is ¥16,655 Mil. RemeGen Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-1,267 Mil. Therefore, RemeGen Co's EV-to-EBITDA ratio for today is -13.14.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, RemeGen Co's Enterprise Value is ¥16,655 Mil. RemeGen Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was ¥1,397 Mil. Therefore, RemeGen Co's EV-to-Revenue ratio for today is 11.92.


RemeGen Co Enterprise Value Historical Data

The historical data trend for RemeGen Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Enterprise Value Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - - - 40,270.79 34,327.87

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,395.08 40,270.79 29,663.46 34,327.87 25,033.24

Competitive Comparison of RemeGen Co's Enterprise Value

For the Biotechnology subindustry, RemeGen Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Enterprise Value falls into.



RemeGen Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

RemeGen Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

RemeGen Co's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co  (SHSE:688331) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

RemeGen Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16655.026/-1539.366
=-10.82

RemeGen Co's current Enterprise Value is ¥16,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-1,539 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

RemeGen Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=16655.026/-1267.354
=-13.14

RemeGen Co's current Enterprise Value is ¥16,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-1,267 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

RemeGen Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16655.026/1396.713
=11.92

RemeGen Co's current Enterprise Value is ¥16,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was ¥1,397 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

No Headlines